Lessons for the clinical nephrologist: legacy effects of bevacizumab and ramucirumab lead to nephrotic syndrome due to renal-limited thrombotic microangiopathy with podocytopathy

J Nephrol. 2024 Sep 17. doi: 10.1007/s40620-024-02087-3. Online ahead of print.

Authors

Takahide Iwasaki¹, Akihiro Kuma², Makoto Yoshida³, Masataka Ikeda⁴, Takahiro Kuragano²

Affiliations

¹ Division of Kidney and Dialysis, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. ta-iwasaki@hyo-med.ac.jp.
² Division of Kidney and Dialysis, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
³ Division of Surgical Pathology, Hyogo Medical University, Nishinomiya, Japan.
⁴ Division of Lower GI, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan.

PMID: 39289295
DOI: 10.1007/s40620-024-02087-3

No abstract available

Keywords: Bevacizumab; Case report; Nephrotic syndrome; Ramucirumab; Thrombotic microangiopathy.